Catalyst Pharmaceuticals Inc
CPRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.85B
Close$
$16.80
46.7% downside
Current Fair Value
46.7% downsideOvervalued by 46.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.85 Billion |
|---|---|
| Enterprise Value | $3.10 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.75 |
| Beta | 0.74 |
| Outstanding Shares | 122,254,171 |
Return
| Return on Equity | 21.85% |
|---|---|
| Return on Assets | 19.29% |
| Return on Invested Capital | 27.65% |
Valuation & Multiples
| P/E Ratio | 17.49 |
|---|---|
| PEG | 141.86 |
| Price to Sales | 7.87 |
| Price to Book Ratio | 3.94 |
| Enterprise Value to Revenue | 5.2 |
| Enterprise Value to EBIT | 11.05 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.48
Average shareholder expectationRevenue Estimate
$155.79 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 131.41% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 29.62%▼ 55.90% |
|---|---|
| Total Invested | $1.14B▼ 56.15% |
| Investors Holding | 166▼ 222.00% |
ESG Score
No data
About Catalyst Pharmaceuticals Inc
CEO: Patrick McEnany